Bayer’s Finerenone Marches Forward, But Is Phase III Design Too Steep A Hill?
This article was originally published in The Pink Sheet Daily
Executive Summary
Heart failure drug's safety profile should become more clear – if the two-indication program hits the mark on dose selection and the evolving standard of care.
You may also be interested in...
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.
Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart
Pfizer's heart failure drug Inspra (eplerenone) has been a spectacular commercial flop since it officially launched in 2004, but the drug could have renewed potential based on the results of new outcomes data. Pfizer announced May 27 that it is halting recruitment in an outcomes trial evaluating Inspra in a broader patient population early due to positive efficacy
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.